Suchergebnisse - "Mertens, Daniel"

PubPharm (98)

31

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

enthalten in: Blood | 2014

von Stilgenbauer, S. | Schnaiter, A. | Paschka, P. | +29

32

Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia

enthalten in: Cancer discovery | 2014

von Oakes, C. | Claus, R. | Gu, L. | +16

33

Prognostic and predictive factors in patients with chronic lymphocytic leukemia : relevant in the era of novel treatment approaches?

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Mertens, D. | Stilgenbauer, S.

CommentOn: J Clin Oncol. 2014 Mar 20;32(9):897-904. - PMID 24516016

34

Prognostic and Predictive Factors in Patients With Chronic Lymphocytic Leukemia: Relevant in the Era of Novel Treatment Approaches?

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2014

von Mertens, D. | Stilgenbauer, S.

35

Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

enthalten in: Cancer discovery | 2014

von Oakes, C. | Claus, R. | Gu, L. | +16

36

In vivo processing assay based on a dual-luciferase reporter system to evaluate DROSHA enzymatic activity

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2014

von Bilan, V. | Allegra, D. | Kuchenbauer, F. | +1

37

Thalidomide regulation of NF-κB proteins limits Tregs activity in chronic lymphocytic leukemia

enthalten in: Advances in clinical and experimental medicine : official organ Wroclaw Medical University | 2014

von Skórka, K. | Bhattacharya, N. | Własiuk, P. | +4

38

Advances in treating chronic lymphocytic leukemia

enthalten in: F1000prime reports | 2014

von Tausch, E. | Mertens, D. | Stilgenbauer, S.

39

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab : results from the CLL2H trial of the GCLLSG

enthalten in: Blood | 2013

von Schnaiter, A. | Paschka, P. | Rossi, M. | +13

40

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

enthalten in: Blood | 2013

von Schnaiter, A. | Paschka, P. | Rossi, M. | +13